MESNA (sodium 2-mercaptoethanesulfonate) for prevention of contrast medium-induced nephrotoxicity - Controlled trial

Clinical Nephrology

Volumn 75, Issue 4, 2011, Pages 302-308

  Ludwig, U ^a   Riedel, M K ^b   Backes, M ^c   Imhof, A ^b   Muche, R ^d   Keller, F ^a  

^a Internal Medicine I   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c ROBERT BOSCH HOSPITAL   (Germany)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

Acute renal failure; Contrast media; Nephrotoxicity prevention; Radiography

Indexed keywords

CONTRAST MEDIUM; CREATININE; CYSTATIN C; IOMEPROL; IOPROMIDE; MESNA; PLACEBO; PROTECTIVE AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANGIOGRAPHY; ARTICLE; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ECHOCARDIOGRAPHY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; KIDNEY DISEASE; KIDNEY FUNCTION TEST; MIDDLE AGED; NONPARAMETRIC TEST; TREATMENT OUTCOME;

AGED; CONTRAST MEDIA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; MESNA; MIDDLE AGED; PLACEBOS; PROTECTIVE AGENTS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 79960947147     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN106651     Document Type: Article

References (38)

1. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002; 39: 930-936.
2. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet. 2005; 365: 417-430.
3. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 997; 103: 368-375.
4. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002; 105: 2259-2264.
5. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA. 1996; 275: 1489-1494.
6. Mashiach E, Sela S, Weinstein T, Cohen HI, Shasha SM, Kristal B. Mesna. a novel renoprotective antioxidant in ischaemic acute renal failure. Nephrol Dial Transplant. 2001; 16: 42-551.
7. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol. 2000; 11: 177-182.
8. Katholi RE,Woods WTJr, Taylor GJ, Deitrick CL, Womack KA, Katholi CR, McCann WP. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis. 1998; 32: 64-71.
9. Shammas NW, Kapalis MJ, Harris M, McKinnea D, Coyne EP. Aminophylline does not protect against radiocontrast nephropathy in patients undergoing percutaneous ngiographic procedures. J Invasive Cardiol. 2001; 13: 738-740.
10. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liebermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000; 343: 180-184.
11. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M et al. Nacetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006; 354: 2773-2782.
12. Dubourg L, Michoudet C, Cochat P, Baverel G. Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide. J Am Soc Nephrol. 2001; 12: 1615-1623.
13. Gressier B, Lebegue N, Brunet C, Luyckx M, Dine T, Cazin M, Cazin JC. Scavenging of reactive oxygen species by letosteine, a molecule with two blocked-SH groups. Comparison with free-SH drugs. Pharm World Sci. 1995; 17: 76-80.
14. Kabasakal L, Sehirli AO, Cetinel S, Cikler E, Gedik N, Sener G. Mesna (2-mercaptoethane sulfonate) prevents ischemia/reperfusion induced renal oxidative damage in rats. Life Sci. 2004; 75: 2329-2340.
15. Sener G, Sehirli O, Ercan F, Sirvanci S, Gedik N, Kacmaz A. Protective effect of MESNA (2-mercaptoethane sulfonate) against hepatic ischemia/reperfusion injury in rats. Surg Today. 2005; 35: 575-580.
16. Skinner R, Sharkey IM, Pearson AD, Craft AW. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol. 1993; 11: 173-190.
17. Haeussler U, Riedel M, Keller F. Free reactive oxygen species and nephrotoxicity of contrast agents. Kidney Blood Press Res. 2004; 27: 167-171.
18. Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol. 2005; 16: 763-773.
19. Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006; 354: 379-386.
20. Harrell FE Jr. Regression modeling strategies. New York: Springer; 2001.
21. Hoffmann U, Fischereder M, Kruger B, Drobnik W, Kramer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. Am Soc Nephrol. 2004; 15: 407-410.
22. Ritz E. N-acetylcysteine and contrast-induced nephropathy. N Engl J Med. 2006; 355: 1499; author reply 1499-1500.
23. Bruce RJ, Djamali A, Shinki K, Michel SJ, Fine JP, Pozniak MA. Background fluctuation of kidney funktion versus contrast-induced nephrotoxicity. Am J Roentgenol. 2009; 192: 711-718.
24. Brar SS, Shen AYJ, Jorgensen MB, Kolewski A, Aharonian VK, Desai N, Ree M et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography. JAMA. 2008; 300: 1038-1046.
25. Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC Jr. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol. 1990; 258: 115-20.
26. Yoshioka T, Fogo A, Beckman JK. Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int. 1992; 41: 1008-1015.
27. Schoenike SE, Dana WJ. Ifosfamide and mesna. Clin Pharm. 1990; 9: 179-191.
28. Ormstad K, Orrenius S, Lastbom T, Uehara N, Pohl J, Stekar J, Brock N. Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat. Cancer Res. 1983; 43: 333-338.
29. Shaw IC, Weeks MS. Interaction between mesna and selected transition metals in vitro and in vivo. Arzneimittelforschung. 1986; 36: 997-1000.
30. Verschraagen M, Zwiers TH, de Koning PE,Welink J, van der Vijgh WJ. Quantification of BNP7787 (dimesna) and its metabolite mesna in human plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl. 2001; 753: 293-302.
31. el-Yazigi A, Ernst P, al-Rawithi S, Legayada E, Raines DA. Pharmacokinetics ofmesna and dimesna after simultaneous intravenous bolus and infusion administration in patients undergoing bone marrow transplantation. J Clin Pharmacol. 1997; 37: 618-624.
32. Smith PF, Booker BM,Creaven P, Perez R, Pendyala L. Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion. J Clin Pharmacol. 2003; 43: 324-1328.
33. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll ardiol. 2003; 41: 2114-2118.
34. Briguori C, Colombo A, Violante A, Balestrieri P, Manganelli F, Paolo Elia P, Golia B et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated ephrotoxicity. Eur Heart J. 2004; 25: 206-211.
35. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation. 2006; 113: 1799-1806.
36. Brar SS, Hiremath S, Dangas G, Mehran R, Brar SK, Leon MB. Sodium bicarbonate for the prevention of contrast-acute kidney injury: a systematic review and meta-analysis. lin J AmSoc Nephrol. 2009; 4: 1584-1592.
37. Seidel A, Andrassy K, Ritz E, Kässer U, Lemmel EM. Allergic reactions to mesna. Lancet. 1991; 338: 381-382.
38. Khaw Sl, Downie PA,Waters KD, Ashley DM, Heath JA. Adverse hypersensitivity reactions to mesna as adjunctive therapy for cyclophosphamide. Pediatr Blood Cancer. 2007; 9: 341-343.